A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

The small study, published recently in the journal Obesity, looked at 34 patients who had already lost weight on GLP-1 ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. But injectable medications aren’t right for everyone. That’s where a new wave of oral GLP-1 ...

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

Research led by Penn Dental's Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as ...

In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.